布地奈德鼻息肉内注射治疗2型慢性鼻窦炎伴鼻息肉的疗效
一项前瞻性双盲随机对照试验纳入150例2型慢性鼻窦炎伴鼻息肉患者,按1:1:1分为口服泼尼松龙组、布地奈德鼻息肉内注射组和生理盐水注射对照组。结果显示口服和注射组的SNOT-22和TNPS评分较对照组显著改善,布地奈德鼻息肉内注射被认为是安全有效的方法。
要点
- 布地奈德鼻息肉内注射每周1次连续5周,可显著改善SNOT-22和TNPS评分。
- 与生理盐水对照组相比,口服泼尼松龙和布地奈德注射组的SNOT-22和TNPS改善均更显著。
- 作者认为鼻息肉内类固醇注射全身副作用有限,对多次复发或高危患者可避免反复口服类固醇。
核心结论
- 鼻息肉内类固醇注射被认为是安全有效的方法,与全身类固醇相比副作用有限。
- 使用布地奈德作为鼻息肉内注射药物似乎有前景。
- 对于多次复发或高危患者,建议避免反复口服类固醇疗程。
研究设计与样本
- 前瞻性双盲对照随机临床试验,纳入150例慢性鼻窦炎伴鼻息肉患者,按1:1:1分为3组。
- A组口服泼尼松龙1 mg/kg每日递减,持续2周。
- B组布地奈德鼻息肉内注射每周1次,连续5周。
- C组鼻息肉内注射生理盐水作为对照组。
主要发现
- SNOT-22评分在所有组中较基线显著改善。
- 口服组和注射组的SNOT-22评分降低幅度远大于对照组(P2 < 0.001,P3 < 0.001)。
- TNPS评分呈相同趋势(P2 < 0.001,P3 < 0.001),但对照组无显著变化。
关键数值与推荐
- 评估指标包括SNOT-22评分、Total Nasal Polyp评分、血清IgE、绝对嗜酸性粒细胞计数和晨皮质醇水平。
- 评估时间点为治疗前、完成治疗方案后1周和6个月。
- 证据等级为2。
临床怎么用
- 作者认为鼻息肉内类固醇注射是安全有效的方法,与全身类固醇相比副作用有限。
- 作者认为使用布地奈德作为鼻息肉内注射药物似乎有前景。
- 作者建议对多次复发或高危患者避免反复口服类固醇疗程。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy and safety of budesonide as an intrapolyp injection in chronic rhinosinusitis with nasal polyps (CRSwNP) in comparison to control and systemic steroids. METHOD: In a prospective double-blinded controlled randomized clinical trial, 150 patients with CRSwNP were divided into 3 groups in a ratio 1:1:1 where group (A) was given oral prednisolone 1 mg/kg tapered daily for 2 weeks, group (B) was given budesonide intrapolyp injection weekly for 5 consecutive weeks, and group (C) was given intrapolyp injection with saline as the control group. Patients were assessed upon Sinonasal Outcome Test (SNOT-22) score, Total Nasal Polyp score (TNPS), Serum IgE, absolute eosinophilic count, and morning cortisol level before treatment, 1 week and 6 months after completing their treatment protocol. RESULTS: SNOT 22 score improved significantly in all groups compared to those at baseline. Reduction in the oral and injection groups was much greater than the control group (P2 < 0.001), (P3 < 0.001), and the same trend concerning TNPS score (P2 < 0.001), (P3 < 0.001) but with no significant change in the control group. CONCLUSION: Intrapolyp steroid injection is considered a safe and effective method in nasal polyposis with limited side effects in comparison to systemic steroids. Using Budesonide as an agent for intrapolyp injection appears to be promising. It's advisable in patients with multiple relapses or high-risk patients to avoid repeated courses of oral steroids. LEVEL OF EVIDENCE: 2 Laryngoscope, 134:2085-2092, 2024.
引用
- Elzayat S, Lasheen H, Gehad I, et al. The Efficacy of Budesonide as Intrapolyp Injection Agent in the Management of Type 2 CRSwNP. Laryngoscope. 2023. PMID: 37916779. doi:10.1002/lary.31137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。